4th Annual RAS Targeted Drug Development Summit

Kongressthemen
For decades, RAS has existed as an elusive therapeutic target, and drugging this high-value oncogene was deemed impossible. Despite this, the first-ever FDA-approved KRAS G12C inhibitor has demonstrated that RAS is in fact druggable and that drugging this protein unlocks a world of successful therapeutic interventions. Now, the future looks bright for treating patients with cancers harboring the RAS mutation.

Kongressorganizer (PCO)
Hanson Wade

https://go.evvnt.com/1209735-2?pid=4832

Frau Erin Thomas